Huakang Biomedical Holdings Company Limited provided group earnings guidance for the nine months ended September 30, 2021. The Board informed the shareholders of the company and potential investors that the Group is expected to record a loss attributable to owners of the Company of approximately RMB 2.3 million for the nine months ended 30 September 2021, representing a significant decrease in loss of approximately RMB 4.3 million comparing with the nine months ended 30 September 2020 of a loss attributable to owners of the Company of approximately RMB 6.6 million.